Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond). 2021;41(11):1183–94.

Article  PubMed  Google Scholar 

Llarena, N.C., Estevez, S.L., Tucker, S.L. and Jeruss, J.S., 2015. Impact of Fertility Concerns on Tamoxifen Initiation and Persistence. J Natl Cancer Inst 107(10), djv202. https://doi.org/10.1093/jnci/djv202. Print 2015 Oct

Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001.

Article  PubMed  Google Scholar 

Vuković P, Kasum M, Raguž J, et al. Fertility preservation in young women with early-stage breast cancer. Acta Clin Croat. 2019;58(1):147–56.

PubMed  PubMed Central  Google Scholar 

Partridge AH, Pagani O, Abulkair O, et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast. 2014;23(3):209–20.

Article  PubMed  Google Scholar 

Lambertini M, Del Mastro L, Pescio MC, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1–7.

Article  PubMed  PubMed Central  Google Scholar 

Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77–106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dinas KD. Impact of breast cancer treatment on fertility. In: Alipour S, Omranipour R, editors. Diseases of the Breast During Pregnancy and Lactation. Cham: Springer International Publishing; 2020. p. 175–9.

Chapter  Google Scholar 

Castillo C, Camejo N. Impact of breast cancer treatments on fertility and the importance of timing for a fertility preservation intervention. Rev Senol Patol Mam. 2022;35(4):305–11. https://doi.org/10.1016/j.senol.2021.08.004.

Article  Google Scholar 

Mauri D, Gazouli I, Zarkavelis G, et al. Chemotherapy associated ovarian failure. Front Endocrinol. 2020;11:1–10.

Article  Google Scholar 

Wenners A, Grambach J, Koss J, et al. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial. BMC Cancer. 2017;17(1):632.

Article  PubMed  PubMed Central  Google Scholar 

Blumenfeld Z. Fertility preservation in women with malignancy: future endeavors. Clin Med Insights Reprod Health. 2019;13:1179558119872490.

Article  PubMed  PubMed Central  Google Scholar 

Çelebi F, Ordu Ç, Ilgün S, et al. The effect of systemic chemotherapy on ovarian function: a prospective clinical trial. Eur J Breast Health. 2020;16(3):177–82.

Article  PubMed  PubMed Central  Google Scholar 

National Cancer Institute. Hormone Therapy for Breast Cancer. July 12, 2022. Available from: https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet

Tremont A, Lu J, Cole JT. Endocrine therapy for early breast cancer: updated review. Ochsner J. 2017;17(4):405–11.

PubMed  PubMed Central  Google Scholar 

Shandley LM, Spencer JB, Fothergill A, et al. Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertil Steril. 2017;107(1):243-252.e5.

Article  CAS  PubMed  Google Scholar 

Kim HJ, Noh WC, Nam SJ, et al. Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: an ASTRRA study report. Eur J Cancer. 2021;151:190–200.

Article  CAS  PubMed  Google Scholar 

National Breast Cancer Foundation. Targeted Therapy. January 17, 2024. Available from: https://www.nationalbreastcancer.org/breast-cancer-targeted-therapy/

Mehta P, Bothra SJ. PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review. Adv Genet. 2021;108:35–80.

Article  CAS  PubMed  Google Scholar 

Li J, Li Q, Zhang L, Zhang S, Dai Y. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function. Biomed Pharmacother. 2023;157:114028.

Article  CAS  PubMed  Google Scholar 

Scavone G, Ottonello S, Blondeaux E, et al. The role of cyclin-dependent kinases (CDK) 4/6 in the ovarian tissue and the possible effects of their exogenous inhibition. Cancers. 2023;15(20):4923. https://doi.org/10.3390/cancers15204923.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong F, Meng T, Li J, et al. Inhibition of CDK4/6 kinases causes production of aneuploid oocytes by inactivating the spindle assembly checkpoint and accelerating first meiotic progression. Biochim Biophys Acta Mol Cell Res. 2021;1868(7):119044.

Article  CAS  PubMed  Google Scholar 

Catlin NR, Bowman CJ, Engel SM, et al. Reproductive and developmental toxicity assessment of palbociclib, a CDK4/6 inhibitor, in Sprague-Dawley rats and New Zealand White rabbits. Reprod Toxicol. 2019;88:76–84.

Article  CAS  PubMed  Google Scholar 

Garutti M, Lambertini M, Puglisi F. Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. ESMO Open. 2021;6(5):100276.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Helgadottir H, Matikas A, Fernebro J, et al. Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors. Eur J Cancer. 2024;202:114010.

Article  CAS  PubMed  Google Scholar 

Charmsaz S, Scott AM, Boyd AW. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors. Exp Hematol. 2017;54:31–40.

Article  CAS  PubMed  Google Scholar 

Mandó P, Waisberg F, Pasquinelli R, et al. HER2-directed therapy in advanced breast cancer: benefits and risks. Onco Targets Ther. 2023;16:115.

Article  PubMed  PubMed Central  Google Scholar 

Lambertini M, Campbell C, Bines J, et al. Adjuvant anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients. J Natl Cancer Inst. 2019;111(1):86–94. https://doi.org/10.1093/jnci/djy094.

Article  CAS  PubMed  Google Scholar 

Levi M, Goshen-Lago T, Yerushalmi R, et al. Anti-HER2/neu antibody reduces chemotherapy-induced ovarian toxicity—From bench to bedside. MDPI AG. 2020. https://doi.org/10.3390/cancers15204923.

Article  Google Scholar 

Poorvu PD, Hu J, Zheng Y, et al. Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. Springer Science and Business Media LLC. 2021

Ruddy KJ, Zheng Y, Tayob N, et al. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021;189(1):103.

Article  CAS  PubMed  Google Scholar 

Cui W, Francis PA, Loi S, et al. Assessment of ovarian function in phase III (neo)adjuvant breast cancer clinical trials: a systematic evaluation. J Clin Oncol. 2021;36(19):1994–2001.

Google Scholar 

Beyer S, Sandu A, White J. Impact and timing of breast cancer radiation therapy and fertility preservation. Curr Breast Cancer Rep. 2020;12(4):375–80.

Article  Google Scholar 

Abdel-Razeq H. Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer. Cancer Manag Res. 2019;11:4273–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bulun SE. Endometriosis. In: Strauss JF, Barbieri RL, editors. Yen and Jaffe’s Reproductive Endocrinology. 8th ed. Philadelphia: Elsevier; 2019. p. 609- 642.e7.

Chapter  Google Scholar 

Li Z, Dong Y, Cao X, Ren S, Zhang Z. Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis. Menopause. 2022;29(9):1093–100.

Article  PubMed  PubMed Central  Google Scholar